Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Suncor Energy Inc. (SU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Suncor Energy Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Suncor Energy Inc. trades at $58.45 (market cap $66.94B). The key difference: Suncor Energy Inc. is far larger — about 14.9× ACADIA Pharmaceuticals Inc.'s market cap, and Suncor Energy Inc. pays a 2.98% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SU | |
|---|---|---|
Market Cap | $4.49B | $66.94B |
Sector | Health | Energy |
52-Week High | $28.06 | $69.73 |
52-Week Low | $20.06 | $38.17 |
Enterprise Value | $3.69B | $75.07B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Suncor Energy (SU) trades at $56.66, up 2.92% today, with a bullish technical signal despite mixed moving averages. The stock shows solid fundamentals with a P/E of 14.82, net margin of 11.62%, and consistent dividend payments, including a recent $0.60 distribution. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed estimates. Analyst consensus is strongly positive with 74% buy ratings.
Outlook remains favorable due to attractive valuation and strong cash flow, but risks include oil price volatility and operational incidents like the recent Sarnia refinery fire. Earnings growth and disciplined capital allocation are key catalysts for upside, while macroeconomic pressures pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
